RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to raps@raps.org so that we can defer those challenges. Your health and safety are paramount to us.

Regulatory Focus™ > News Articles > BREAKING: Congress Seeks Dozens of Major Regulatory Reforms in New Bill

BREAKING: Congress Seeks Dozens of Major Regulatory Reforms in New Bill

Posted 27 January 2015 | By Alexander Gaffney, RAC, 

BREAKING: Congress Seeks Dozens of Major Regulatory Reforms in New Bill

The US House of Representatives' Energy and Commerce (E&C) Committee today released a long-anticipated discussion draft of its 21st Century Cures Act, an ambitious attempt to overhaul the way the US Food and Drug Administration (FDA) regulates new healthcare products in the hopes of incentivizing the creation of new products to treat patients.

The 393-page draft contains five main sections, as well as dozens of subtitles:

  • Title I—Putting Patients First By Incorporating Their Perspectives Into The Regulatory Process And Addressing Unmet Needs
  • Title II—Building The Foundation For 21st Century Medicine, Including Helping Young Scientists
  • Title III—Modernizing Clinical Trials
  • Title IV—Accelerating The Discovery, Development, And Delivery Cycle And Continuing 21st Century Innovation At NIH, FDA, CDC, And CMS
  • Title V—Modernizing Medical Product Regulation

Regulatory Focus will have an update tomorrow explaining some of the bill's major provisions. For insight and analysis into all FDA-related legislation, please see our tracker here.

 

© 2022 Regulatory Affairs Professionals Society.

Tags: 21st Century Cures Act, Congress, FDA Legislation, House, Energy and Commerce Committee